Rocket Pharmaceuticals, Inc. - Common Stock (RCKT)
2.9600
+0.1900 (6.86%)
NASDAQ · Last Trade: Jun 4th, 1:25 AM EDT
Detailed Quote
Previous Close
2.770
Open
2.760
Bid
2.960
Ask
2.990
Day's Range
2.710 - 3.040
52 Week Range
4.550 - 26.98
Volume
7,831,079
Market Cap
194.88M
PE Ratio (TTM)
-1.125
EPS (TTM)
-2.6
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,927,076
Chart
About Rocket Pharmaceuticals, Inc. - Common Stock (RCKT)
Rocket Pharmaceuticals Inc is a biotechnology company focused on developing innovative gene therapies to treat rare and devastating diseases. Its mission revolves around leveraging advanced genetic science and technology to create transformative therapies that can address the underlying causes of genetic disorders. The company primarily targets conditions that currently lack effective treatment options, with the aim of providing significant clinical benefits and improving the quality of life for patients. By utilizing cutting-edge research and collaborating with leading experts in the field, Rocket Pharmaceuticals strives to bring groundbreaking solutions to the forefront of healthcare. Read More
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Rocket Pharmaceuticals said that it is working with the FDA to ensure safety of all study patients and resume the trial “as expeditiously as possible."
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to RP-A501, its investigational gene therapy for Danon disease.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced preliminary data from the Phase 1 clinical trial of RP-A601 for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM). RP-A601 showed a well-tolerated safety profile with no dose-limiting toxicities, increased PKP2 protein expression, and preliminary indications of improvement or stabilization in arrhythmia burden, heart function, and quality of life in all three patients followed for up to 12 months. Results were presented today as a late-breaking oral presentation at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) and will be discussed on a company webinar today at 4:30 p.m. ET.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the company will be presenting data for the first time from the Phase 1 clinical trial of RP-A601 to treat patients with plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM) at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held from May 13-17 in New Orleans, LA.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the first quarter ending March 31, 2025.
